Unlock stock picks and a broker-level newsfeed that powers Wall Street.
5.90
-0.27
(-4.38%)
At close: April 4 at 5:29:43 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
334,672
334,672
16,840
15,283
10,478
Cost of Revenue
5,095
5,095
5,059
4,475
4,630
Gross Profit
329,577
329,577
11,781
10,808
5,848
Operating Expense
90,462
90,462
91,127
236,527
417,418
Operating Income
239,115
239,115
-79,346
-225,719
-411,570
Net Non Operating Interest Income Expense
-34,864
-34,864
-23,215
-14,116
-10,601
Pretax Income
207,021
207,021
-104,280
-218,179
-418,380
Tax Provision
18,315
18,315
-8,470
-6,610
-7,482
Net Income Common Stockholders
188,706
188,706
-95,810
-211,569
-410,898
Diluted NI Available to Com Stockholders
188,706
188,706
-95,810
-211,569
-410,898
Basic EPS
-0.74
1.77
-1.52
-2.87
-5.58
Diluted EPS
-0.74
1.76
-1.52
-2.87
-5.58
Basic Average Shares
107,112.71
106,391.03
63,067.89
73,725.21
73,725.75
Diluted Average Shares
107,112.71
107,260.18
63,067.89
73,725.21
73,725.80
Total Operating Income as Reported
241,885
241,885
-81,065
-225,373
-411,570
Total Expenses
95,557
95,557
96,186
241,002
422,048
Net Income from Continuing & Discontinued Operation
188,706
188,706
-95,810
-211,569
-410,898
Normalized Income
188,706
188,706
-95,810
-233,010.06
-415,214.87
Interest Income
5,128
5,128
3,131
593
247
Interest Expense
39,992
39,992
26,346
11,951
10,848
Net Interest Income
-34,864
-34,864
-23,215
-14,116
-10,601
EBIT
247,013
247,013
-77,934
-206,228
-407,532
EBITDA
254,674
254,674
-68,283
-198,410
-398,859
Reconciled Cost of Revenue
5,095
5,095
5,059
4,475
4,630
Reconciled Depreciation
7,661
7,661
9,651
7,818
8,673
Net Income from Continuing Operation Net Minority Interest
188,706
188,706
-95,810
-211,569
-410,898
Total Unusual Items Excluding Goodwill
--
--
--
22,127
4,396
Total Unusual Items
--
--
--
22,127
4,396
Normalized EBITDA
254,674
254,674
-68,283
-220,537
-403,255
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
685.94
79.13
12/31/2021 - 4/22/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ONCO.ST Oncopeptides AB (publ)
1.6660
-2.34%
XBRANE.ST Xbrane Biopharma AB (publ)
0.1800
-4.66%
ISOFOL.ST Isofol Medical AB (publ)
1.9580
-5.64%
ATORX.ST Alligator Bioscience AB (publ)
0.0055
-9.84%
FLUO.ST FluoGuide A/S
35.80
+0.85%
GUBRA.CO Gubra A/S
373.00
-10.34%
HNSA.ST Hansa Biopharma AB (publ)
21.70
-4.15%
4588.T Oncolys BioPharma Inc.
532.00
-3.10%
CMOTEC-B.ST Scandinavian ChemoTech AB (publ)
1.3800
+1.10%
PEG.CO Pharma Equity Group A/S
0.1380
-1.08%